Xtant Medical stock draws a USD 1.00 target from Lucid Capital

Lucid Capital Markets initiated coverage on Xtant Medical stock with a Buy rating and a $1.00 price target, despite the company reporting a significant 35% year-over-year revenue decline and a net loss in its second quarter. The analyst target is predicated on the potential of Xtant Medical's regenerative medicine products and a new distribution partnership with BioHorizons for its Prolifica product in the US and Canada. The investment case is framed by expanding commercial reach through the par